These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 21074059)

  • 41. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
    Di Giacomo AM; Margolin K
    Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.
    Millward M; Underhill C; Lobb S; McBurnie J; Meech SJ; Gomez-Navarro J; Marshall MA; Huang B; Mather CB
    Br J Cancer; 2013 May; 108(10):1998-2004. PubMed ID: 23652314
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overcoming immunological tolerance to melanoma: Targeting CTLA-4.
    Hodi FS
    Asia Pac J Clin Oncol; 2010 Mar; 6 Suppl 1():S16-23. PubMed ID: 20482528
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The ipilimumab lesson in melanoma: achieving long-term survival.
    Delyon J; Maio M; Lebbé C
    Semin Oncol; 2015 Jun; 42(3):387-401. PubMed ID: 25965357
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase 2 study of tremelimumab in patients with advanced uveal melanoma.
    Joshua AM; Monzon JG; Mihalcioiu C; Hogg D; Smylie M; Cheng T
    Melanoma Res; 2015 Aug; 25(4):342-7. PubMed ID: 26050146
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
    Vonderheide RH; LoRusso PM; Khalil M; Gartner EM; Khaira D; Soulieres D; Dorazio P; Trosko JA; Rüter J; Mariani GL; Usari T; Domchek SM
    Clin Cancer Res; 2010 Jul; 16(13):3485-94. PubMed ID: 20479064
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy).
    Bakacs T; Mehrishi JN; Szabó M; Moss RW
    Pharmacol Res; 2012 Aug; 66(2):192-7. PubMed ID: 22503629
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Treatment of metastatic melanoma with CTLA4 antibodies].
    Hafner C
    Hautarzt; 2010 Sep; 61(9):808-10. PubMed ID: 20721523
    [No Abstract]   [Full Text] [Related]  

  • 49. Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma.
    Wang E; Kang D; Bae KS; Marshall MA; Pavlov D; Parivar K
    J Clin Pharmacol; 2014 Oct; 54(10):1108-16. PubMed ID: 24737343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
    Comin-Anduix B; Lee Y; Jalil J; Algazi A; de la Rocha P; Camacho LH; Bozon VA; Bulanhagui CA; Seja E; Villanueva A; Straatsma BR; Gualberto A; Economou JS; Glaspy JA; Gomez-Navarro J; Ribas A
    J Transl Med; 2008 May; 6():22. PubMed ID: 18452610
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
    Weber J
    Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [New hope in metastatic melanoma treatment?].
    Guillot B
    Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
    [No Abstract]   [Full Text] [Related]  

  • 53. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody.
    Camacho LH
    Expert Opin Investig Drugs; 2008 Mar; 17(3):371-85. PubMed ID: 18321236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Melanoma drug wins US approval.
    Ledford H
    Nature; 2011 Mar; 471(7340):561. PubMed ID: 21455150
    [No Abstract]   [Full Text] [Related]  

  • 55. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.
    Tarhini AA; Kirkwood JM
    Expert Opin Biol Ther; 2008 Oct; 8(10):1583-93. PubMed ID: 18774925
    [TBL] [Abstract][Full Text] [Related]  

  • 56. From ASCO-targeted therapies: Anti-PD-1 approaches--important steps forward in metastatic melanoma.
    Razzak M
    Nat Rev Clin Oncol; 2013 Jul; 10(7):365. PubMed ID: 23752732
    [No Abstract]   [Full Text] [Related]  

  • 57. Ipilimumab: a promising immunotherapy for melanoma.
    Thumar JR; Kluger HM
    Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.
    Eroglu Z; Kim DW; Wang X; Camacho LH; Chmielowski B; Seja E; Villanueva A; Ruchalski K; Glaspy JA; Kim KB; Hwu WJ; Ribas A
    Eur J Cancer; 2015 Nov; 51(17):2689-97. PubMed ID: 26364516
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment of metastatic melanoma: are we entering the era of targeted treatment?].
    von Moos R; Cathomas R; Mark M; Hitz F
    Praxis (Bern 1994); 2012 Oct; 101(22):1423-9. PubMed ID: 23117962
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?
    Pennock GK; Waterfield W; Wolchok JD
    Am J Clin Oncol; 2012 Dec; 35(6):606-11. PubMed ID: 21336089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.